The US Court of Appeals for the Federal Circuit concluded that The Medicines Co.'s agreement for the distribution of Angiomax (bivalirudin) was a commercial offer for sale, but it has left it for a district court to decide if the agreement covers the patent on TMC's improved manufacturing process.
In its Feb. 6 decison in The Medicines Company v. Hospira Inc. the court further clarifies the application...





